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CASE PRESENTATION
A female in her 30s developed renal failure secondary to
mixed connective tissue disease-associated immune
complex glomerulonephritis. Her past medical and family
history was otherwise unremarkable. She underwent a
pre-emptive renal transplantation from her mother,
receiving induction with dacluzimab and had an
uneventful post-transplant course. Her immunosuppressive
regimen at discharge included prednisone 5 mg daily,
mycophenolate mofetil 1000 mg twice daily, tacrolimus
4 mg twice daily, and prophylaxis with oral gancyclovir
and trimethoprim–sulfamethoxazole, atenolol for
hypertension, and famotidine, iron and calcium/vitamin
D supplements. Her baseline serum creatinine after
the transplant was 1.5 mg/dl.
Two years after receiving the transplant, she developed
fever and dysuria and was treated for a presumed urinary
tract infection (negative urine cultures). Her serum
creatinine during this episode increased to 1.9 mg/dl and
remained elevated in this range. Her physical examination
was unremarkable and her blood pressure was 130/80 mm
Hg. A renal ultrasound did not show any abnormalities.
A renal biopsy was performed.
RENAL BIOPSY FINDINGS
Sampling for light microscopy consisted of a single core of
renal cortex containing eight glomeruli, all of which appeared
histologically unremarkable. There was diffuse, moderate to
severe interstitial inflammation involving the entire cortex
sampled, and composed of lymphocytes and less prominent
plasma cells. The interstitial inflammation extended across
tubular basement membranes to produce extensive tubulitis
with multiple tubules containing greater than 10 lympho-
cytes. Proximal tubules also displayed diffuse degenerative
changes and interspersed, enlarged, hyperchromatic nuclei
with intranuclear viral inclusions typical of BK virus. This
diagnosis was subsequently confirmed by immunohisto-
chemical staining for SV40. There was moderate tubular
atrophy and interstitial fibrosis involving 50% of the cortex
sampled. Blood vessels appear unremarkable (Figure 1).
The renal biopsy findings were diagnostic of BK virus-
associated interstitial nephritis (BKVIN). In the light of the
diffuse distribution of the interstitial inflammation and
tubulitis but more localized viral inclusions, the possibility of
coexistent acute cellular rejection could not be excluded.
DISCUSSION
BK virus is a circular, double-stranded DNA virus.1 In total,
70–85% of people are infected at some point in their lifetime,
most frequently during childhood. The virus is likely
transmitted through the respiratory route before establishing
life-long latency in the urinary epithelium. It normally
remains quiescent unless the immune system is impaired. It
appears that T-cell mediated immunity keeps viral replication
in check; renal transplant patients with antibodies directed
against BK virus may still progress to nephropathy. Studies
show that viral reactivation occurs in patients after solid
organ transplantation, bone marrow transplantation, and in
patients with human immunodeficiency virus/acquired
immunodeficiency syndrome. Despite case reports of BKVIN
after heart transplantation and in patients with HIV/AIDS,
BKVIN as a cause of renal dysfunction is rare outside of renal
transplantation.2,3
Reactivation of BK virus may manifest in several different
forms (Table 1). Asymptomatic viral replication, hemo-
rrhagic cystitis, ureteral stricture, and viral interstitial
nephritis/BK virus associated nephropathy have all been
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described. Among renal transplant recipients, the incidence
of asymptomatic urinary shedding of virus ranges from 30 to
40%. The rate of BKVIN is lower, ranging from 1 to 10% in
recent series, but may be increasing.4 Rates of graft loss range
from 10 to 80%. Most cases present within the first year after
transplantation, although the disease can develop at any time.
Risk factors for BKVIN have not fully been defined, but
intensity of immunosuppression likely plays a key role.
Treatment of rejection with intravenous steroids or antilympho-
cyte preparations increases the risk of developing BKVIN,
but induction therapy with these preparations may not be
associated.5 It is suggested that the combination of tacro-
limus (TAC) and mycophenolate (MMF) may be particularly
potent at inducing BKVIN, but this too is not entirely
clear. In a recent prospective study that included BK virus
monitoring, 46% of patients on TACþMMF developed viruria,
as did 41% of patients on a regimen of cyclosporine and
azathioprine (AZA). There was no independent effect of
TAC, cyclosporine, MMF, or AZA on viruria or viremia.6
Early reports suggest that immunosuppression superimposed
on mechanical and ischemic damage could predispose to BK
virus-associated ureteral stenosis.7 Additional factors that
may predispose to BKVIN include: male gender, white race,
human leukocyte antigen mismatch, and ureteral stent
usage.4 The frequent presence of tubulitis makes concomitant
rejection difficult to diagnose and may not respond to
antirejection therapies.8
The recommendations of the 2003 consensus conference
are that all renal transplant recipients should be screened for
BK virus replication in the urine: (1) every 3 months during
the first 2 years post-transplant; (2) when allograft dysfunc-
tion is noted; and (3) when allograft biopsy is performed. A
positive screening result should be confirmed within 4 weeks
and assessed by quantitative assays (e.g. BK viral load in
plasma or urine). Definitive diagnosis of BKVIN requires
allograft biopsy. If BKVIN and concurrent acute rejection is
diagnosed, antirejection treatment should be considered,
followed by reduction in immunosuppression.4
Treatment options for BKVIN
Treatment recommendations must be tempered by the fact
that there are no well-conducted randomized trials on
treatment strategies and no universally effective antiviral
medications. Principles of treatment fall in two categories:
modification of immunosuppression to restore antiviral
immunity and specific antiviral therapy to reduce viral
replication (Table 2).
Modification of immunosuppressive regimen
Prior to the discovery of medications with antiviral activity,
treatment was limited to reducing immunosuppression. The
optimal way to do this while providing adequate immuno-
suppression to prevent rejection remains debated. In a report
on 100 patients by Ramos et al.,9 patients maintained on a
single immunosuppressant (TAC, cyclosporine, sirolimus)
and prednisone were more likely to clear the virus and had
less graft loss than those maintained on reduced dose of two
immunosuppressants with continued prednisone. However,
this was not a randomized trial. A successful immuno-
suppression reduction strategy may be gleaned from the
prospective trial mentioned above.6 Two hundred patients
received rabbit antithymocyte globulin (Thymoglobulins
from Sangstat, Fremont, CA, USA) for induction followed by
TAC or cyclosporine, prednisone, and AZA (low risk) or
MMF (high risk) as the third drug. Patients were prospec-
tively screened for BK virus replication with plasma and urine
polymerase chain reaction, and patients with BK viremia had
AZA or MMF withdrawn. If this was unsuccessful at clearing
viremia, calcineurin inhibitor doses were reduced. Thirty-five
percent of patients developed viruria; 11.5% developed
viremia. Viremia resolved in 22 of 23 patients with reduction
in immunosuppression, but only five of 23 cleared their
viruria. Seven patients responded to withdrawal of AZA/
MMF alone, two patients responded to reduction in
calcineurin inhibitor dosage alone, six patients required
cessation of AZA/MMF and additional reduction in calci-
neurin inhibitor, and seven patients cleared their infection











Figure 1 | BK virus inclusion in renal epithelial cells: nuclear
enlargement with ‘smudgy’ appearance (arrow).
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with standard tapering of immunosuppression after trans-
plantation. Remarkably, there were no cases of biopsy-proven
BKVIN in this cohort. Patients were only biopsied for graft
dysfunction, not viremia, so mild cases of intrarenal viral
replication may have been missed. Reduction in immuno-
suppression was associated with only one episode of
rejection.
As an alternative to removing immunosuppressant agents,
some authors have tried switching to calcineurin inhibitor-
free regimens on the premise that renal epithelial cell toxicity
of calcineurin inhibitors may be permissive to viral replica-
tion. Wali et al.10 reported switching three patients from a
regimen of TAC/MMF/prednisone to sirolimus/prednisone
for biopsy-proven BKVIN. All three patients cleared their
viremia at 18 months follow-up with improvement in mean
serum creatinine from 1.8 to 1.5. It is important to recognize
that this regimen does not distinguish a generalized effect of
immunosuppression reduction from a specific benefit of
sirolimus in BKVIN. Several cases of BKVIN have recently
been reported in patients receiving sirolimus-based regi-
mens.11
A final immunomodulation strategy that may become
available in the future is the ex vivo manipulation of T cells to
enhance BK virus-specific immunity.12 This leaves open the
possibility of providing specific immunity against the virus,
while avoiding the increased risk of rejection associated with
decreased immunosuppression.
Specific antiviral therapy
Cidofovir (Vistides) is a cytidine nucleotide analog that has
been used to treat cytomegalovirus (CMV) retinitis and JC
virus associated progressive multifocal leukoencephalopathy.
The use of cidofovir in renal transplantation is limited by its
nephrotoxicity. In trials using cidovir to treat CMV retinitis,
50% of patients developed proteinuria (4100 mg/dl), and
24% developed serum creatinine concentrations 41.5 mg/dl.
The first reported use of cidofovir specifically for BK virus
infection was the successful treatment of hemorrhagic cystitis
in a bone marrow transplant recipient.13 Bjorang et al.14
treated one renal transplant recipient with BKVIN with
cidovir at a reduced dose to limit nephrotoxicity (taking
advantage of the fact that cidovir is concentrated in the
kidney providing adequate tissue concentration at a lower
dose). Treatment was initiated at 0.25 mg/kg after 2 h of
hydration with normal saline and was increased to 0.45 mg/
kg per dose given every 2 weeks. Treatment resulted in
clearance of virus from the blood and reduction in viruria.
Since then, there have been several other case reports using
cidofovir at doses ranging from 0.25 to 1 mg/kg every 2–3
weeks showing clearance of viremia in many.15 These patients
also underwent reduction in immunosuppression so it is
difficult to distinguish the direct antiviral effect of cidofovir
from the benefit of enhanced immune response. Unfortu-
nately, many patients in these reports were also left with a
significant amount of renal dysfunction and interstitial
fibrosis.
Leflunomide (Aravas) is metabolized to its active
metabolite A77 1726, which inhibits dihydroorate dehydro-
genase, an enzyme involved in pyrimidine synthesis.
Leflunomide has mainly been used to treat rheumatoid
arthritis, but it has also been used in solid organ
transplantation as primary immunosuppression. In vitro
experiments suggest that leflunomide may also inhibit
tyrosine kinase activity and that this inhibition of protein
phosphorylation may be responsible for its antiviral effects.16
Williams et al.17 recently reported on outcomes of 17 patients
treated with leflunomide for BKVIN. Fifteen of 17 patients
showed either clearance of viremia (7 of 15) or reduction in
serum viral load. Interestingly, the two patients without
virologic response also showed persistent levels of A77 1726
below 40 mg/ml suggesting the need for a minimum
therapeutic concentration. Serum creatinine stabilized or
improved in the 15 patients with blood levels above 40 mg/ml.
Leflunomide’s main side effects are leucopenia, rash, and hair
loss. The half-life of the active metabolite, A77 1726 is
approximately 2 weeks. FK778, an analog of the active
metabolite of leflunomide with a shorter half-life, is currently
undergoing clinical trials both for maintenance immuno-
suppression in renal transplantation and in a trial to
specifically treat patients with BKVIN.
Retransplantation in BKVIN
In patients who lose their allografts due to BKVIN, questions
remain whether retransplantation is safe and whether
transplant nephrectomy would reduce the rate of recurrent
infection. Transplant nephrectomy has been associated with
resolution of viremia, although immunosuppression was
reduced at the same time.18 Retransplantation in 10 patients
after graft loss from BK virus infection was associated with
recurrent infection in only one patient after a mean of 13.3
months follow-up. The recurrent infection occurred in a
patient who had previously undergone transplant nephrect-
omy.19 There are inadequate data to give firm recommenda-
tions on retransplantation after allograft loss due to BKVIN,
but it seems prudent to ensure clearance of viremia, either
through withdrawal of immunosuppression alone or possibly
removal of the allograft if viremia persists.
FOLLOW-UP
In our patient, plasma BK virus titers at time of biopsy were
8 106 copies/ml and urine titers were 41.3 109 copies/ml.
The doses of TAC and sirolimus were reduced to target levels
o5 ng/ml. Cidofovir 0.25 mg/kg/dose was administered at
2-weekly intervals. Her creatinine increased to 2.5 mg/dl.
Repeat renal allograft biopsy again revealed diffuse and severe
interstitial inflammation and tubulitis. Intranuclear viral
inclusions were less prominently seen and a smaller
percentage of cells stained positively for SV40 (a marker of
BK virus infection). As a result, the patient was thought to
possibly have BKVIN and concurrent acute cellular rejection.
She received three-500 mg doses of intravenous methylpred-
nisolone, and sirolimus was replaced with leflunomide at a
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dose of 20 mg every other day. The patient was noted to be
pregnant 5 months after starting leflunomide (contraceptive
failure). Leflunomide was discontinued and 11 days of
cholestyramine was administered to facilitate leflunomide
removal. AZA was initiated at 75 mg/day at this time. She
delivered a preterm infant after which leflunomide was
resumed. Both mother and child are doing well at this time
and the patient’s serum creatinine at last follow-up (2 years
after diagnosis of BK virus nephropathy) was 1.6 mg/dl. Her
plasma BK virus (quantitative) remains negative.
CONCLUSION
Reactivation of BK virus is being increasingly recognized as a
cause of allograft dysfunction and can lead to allograft loss.
All renal transplant recipients should be screened for BK virus
replication early in the transplant course or when allograft
dysfunction is noted. Definitive diagnosis of BKVIN requires
allograft biopsy. If BKVIN and concurrent acute rejection is
diagnosed, antirejection treatment should be considered,
coupled with subsequently reducing immunosuppression.
Reduction of immunosuppression has been associated with
clearance of viremia in asymptomatic patients. Leflunomide
may be associated with clearance of viremia and stabilization
of renal function. Cidofovir at low doses (0.25–0.33 mg/kg
intravenously biweekly) without probenicid could be con-
sidered for refractory cases. Retransplantation after renal
allograft loss to BKVIN remains a treatment option for
patients who have cleared viremia.
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